JSH-23 (Synonyms: NFκB Activation Inhibitor II) |
| Catalog No.GC11438 |
JSH-23, exhibited inhibitory effect on nuclear translocation and NF-κB transcriptional activity with an IC50 value of 7.1 µM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 749886-87-1
Sample solution is provided at 25 µL, 10mM.
JSH-23 exhibited an inhibitory effect on nuclear translocation and NF-κB transcriptional activity with an IC50 value of 7.1 µM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7 [1].
JSH-23 (1 µM) monotherapy significantly reduced the chemotactic sensitivity of the cells to SDF1. The co-treatment with cordycepin (10 µM) and JSH-23 (1 µM) significantly inhibited the expression of CXCR4 [2].
JSH-23 (1 and 3 mg/kg) treatment significantly reversed the nerve conduction and nerve blood flow deficits seen in diabetic animals [1]. Protein expression studies showed that nuclear translocation of the p65/p50 subunit was inhibited by JSH-23 treatment in the sciatic nerve. The treatment also lowered the elevated IL-6, TNF-α, cyclo-oxygenase (COX-2), and inducible nitric oxide synthase (iNOS) levels/expression [1]. Mice were treated with JSH-23 (20 or 40 mg/kg) which directly affects NF-κB transcriptional activity. Kidney function, tubular injury (ATN, serum neutrophil gelatinase-associated lipocalin [NGAL], but not apoptosis) and myeloperoxidase (MPO) activity were significantly improved by JSH-23 (40 mg/kg) [3].
References:
[1]. Kumar A, Negi G, Sharma S S. JSH 23 targets nuclear factor kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defense [J]. Diabetes, Obesity and Metabolism, 2011, 13(8): 750-758.
[2]. Guo Z, Chen W, Dai G, et al. Cordycepin suppresses the migration and invasion of human liver cancer cells by downregulating the expression of CXCR4[J]. International journal of molecular medicine, 2020, 45(1): 141-150.
[3]. Ozkok A, Ravichandran K, Wang Q, et al. NF-κB transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI)[J]. Toxicology letters, 2016, 240(1): 105-113.
| Cell experiment [1]: | |
Cell lines | Normal human lung epithelial cell line BEAS-2B and human lung cancer cell line A549 |
Preparation Method | Cells were treated with different concentrations of NF-κB inhibitor JSH-23 (5, 10, 20, 30, 40, and 50 µM, respectively) for 24 h. |
Reaction Conditions | 5, 10, 20, 30, 40, and 50 µM for 24 hours |
Applications | With the increase in JSH-23 concentration, the inhibition rate for cell viability was gradually increased, and significant differences existed when the JSH-23 concentration was greater than 20 µM. |
| Animal experiment [2]: | |
Animal models | Male 12-week-old normotensive Wistar rats and Prague hereditary hypertriglyceridemic (HTG) rats |
Preparation Method | Mice were given a total dose of either 20 mg/kg of JSH-23 (10 mg/kg 8 h prior to cisplatin injection and 5 mg/kg on days 1 and 2 after cisplatin injection) or a total dose of 40 mg/kg body weight of JSH-23 (20 mg/kg 8 h prior to cisplatin injection and 20 mg/kg on day 1 after cisplatin injection) or vehicle (DMSO). |
Dosage form | Intraperitoneal injection, 5, 10, 20 mg/kg |
Applications | JSH-23 (total dose of 40 mg/kg) resulted in a significant decrease in BUN, serum creatinine and serum NGAL. NGAL is an early diagnostic biomarker of cisplatin-induced AKI. JSH-23 had no effect on BUN and serum creatinine in vehicle-treated mice (Fig. 2). |
References: | |
| Cas No. | 749886-87-1 | SDF | |
| Synonyms | NFκB Activation Inhibitor II | ||
| Chemical Name | 4-methyl-1-N-(3-phenylpropyl)benzene-1,2-diamine | ||
| Canonical SMILES | CC1=CC(=C(C=C1)NCCCC2=CC=CC=C2)N | ||
| Formula | C16H20N2 | M.Wt | 240.34 |
| Solubility | ≥ 24mg/mL in DMSO | Storage | Store at -20° C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.1608 mL | 20.8039 mL | 41.6077 mL |
| 5 mM | 0.8322 mL | 4.1608 mL | 8.3215 mL |
| 10 mM | 0.4161 mL | 2.0804 mL | 4.1608 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *